SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

• ClinicalTrials.gov Identifier: NCT00418938
• Recruitment Status: Completed
• First Posted: January 5, 2007
• Results First Posted: March 28, 2014
• Last Update Posted: October 17, 2018
• Sponsor: Amgen
• Information provided by (Responsible Party): Amgen

Study Description

Brief Summary:

This is a multi-center, open-label, randomized, phase 2, two-arm clinical trial to be conducted in the United States. Approximately 210 eligible KRAS wild-type expressing metastatic colorectal cancer subjects who have failed first-line oxaliplatin-based chemotherapy (with at least 4 doses of oxaliplatin-based chemotherapy) with at least 4 doses of bevacizumab (failure is defined as toxicity due to oxaliplatin-based chemotherapy or progression of disease on first-line treatment) will be randomized in a 1:1 ratio to receive either a once-every-two-weeks (Q2W) FOLFIRI regimen plus panitumumab 6 mg/kg or a Q2W FOLFIRI regimen plus bevacizumab (either 5 mg/kg or 10 mg/kg, depending on physician choice and institutional standard of care).

Condition or disease	Intervention/treatment	Phase
Cancer; Colon Cancer; Colorectal Cancer; Metastatic Cancer; Rectal Cancer; Metastatic Colorectal Cancer	Drug: Panitumumab; Drug: Bevacizumab; Drug: Leucovorin; Drug: Irinotecan; Drug: 5-Fluorouracil	Phase 2

Detailed Description:

This phase 2, multicenter, open-label, randomized, two-arm study was designed to estimate the treatment effect of panitumumab in combination with FOLFIRI compared to bevacizumab in combination with FOLFIRI in subjects with metastatic colorectal cancer (mCRC) who had failed first-line therapy with at least 4 doses of oxaliplatin-based chemotherapy and bevacizumab. After data became available demonstrating that the treatment effect of antiepidermal growth factor receptor (EGFR) agents was limited to patients with wild-type Kirsten rat Sarcoma-2 virus (KRAS) mCRC, the study was amended to enroll only subjects with wild-type KRAS tumors. Eligible subjects were randomized in a 1:1 ratio to receive panitumumab 6 mg/kg plus FOLFIRI once every 2 weeks (Q2W) or bevacizumab 5 mg/kg or 10 mg/kg plus FOLFIRI Q2W. Randomization was stratified by the reason for first-line treatment failure (progression vs toxicity) and by intended bevacizumab dose (5 mg/kg vs 10 mg/kg). The intended bevacizumab doses were ascertained from sites at the time of site initiation. Subjects were treated with all or any components of second-line treatment until the occurrence of unacceptable adverse events, disease progression, death, loss to follow up, or study withdrawal by the subject, investigator, or sponsor. Tumor response was evaluated by blinded central radiology review per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 and by the investigator using either modified RECIST version 1.0 or clinical assessment. After subjects permanently discontinued all components of second-line treatment, they were to undergo a safety follow-up assessment 30 (± 7) days after the last dose. Subjects ending second-line treatment before disease progression were followed for PFS (radiographic disease assessment) every 12 weeks (± 14 days) from the safety follow-up visit until disease progression, initiation of a new therapy for mCRC, or until approximately 100 PFS events were observed in subjects with wild-type KRAS tumors. Subjects were also followed for survival every 12 weeks (± 14 days) from the safety follow-up assessment until approximately 100 PFS events were observed in subjects with wild-type KRAS tumors.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 266 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI With Either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Tumors
• Actual Study Start Date: November 1, 2006
• Actual Primary Completion Date: May 10, 2012
• Actual Study Completion Date: April 1, 2013

Arms and Interventions

Arm	Intervention/treatment
Experimental: Arm A; FOLFIRI + Panitumumab	Drug: Panitumumab; 6mg/kg IV; Drug: Leucovorin; 400mg/m^2 IV (in the vein); Drug: Irinotecan; 180mg/m^2 IV (in the vein); Drug: 5-Fluorouracil; 400mg/m^2 bolus IV (in the vein) over 2-4 min, followed by 2400mg/m^2 continuous IV over 46 hours for the first 2 cycles, increased to 3000mg/m^2 thereafter if no significant side effects
Experimental: Arm B; FOLFIRI + Bevacizumab	Drug: Bevacizumab; Either 5mg/kg OR 10mg/kg IV; Drug: Leucovorin; 400mg/m^2 IV (in the vein); Drug: Irinotecan; 180mg/m^2 IV (in the vein); Drug: 5-Fluorouracil; 400mg/m^2 bolus IV (in the vein) over 2-4 min, followed by 2400mg/m^2 continuous IV over 46 hours for the first 2 cycles, increased to 3000mg/m^2 thereafter if no significant side effects

Outcome Measures

Primary Outcome Measures :

1. Progression-free Survival (PFS) [ Time Frame: From randomization up to 65 months. ]
   Progression-free survival is defined as time from the date of randomization to the date of first progression per modified RECIST version 1.0 (based on central review of the radiographic scans), or death within 60 days after the last evaluable tumor assessment or randomization date (whichever is later).

Secondary Outcome Measures :

1. Overall Survival [ Time Frame: From randomization up to 65 months. ]
   Overall survival is defined as time from the date of randomization to the date of death due to any cause. Subjects who have not died or are lost to follow-up at the analysis cutoff date will be censored at their last contact date.
2. Objective Response Rate [ Time Frame: From randomization up to 65 months. ]
   Objective response rate is defined as incidence of either a confirmed complete response (CR) or partial response (PR) on study up to starting a new anti-tumor therapy and will be based on modified RECIST version 1.0 (responder) by central assessment.
3. Time to Response [ Time Frame: From randomization up to 65 months. ]
   Time to response is defined as time from the date of randomization to the date of first confirmed objective response
4. Time to Progression [ Time Frame: From randomization up to 65 months. ]
   Time to progression is defined as time from the date of randomization to the date of radiographic disease progression per modified RECIST version 1.0 (per central assessment).
5. Disease Control [ Time Frame: From randomization up to 65 months. ]
   Disease control is defined as incidence of objective response or stable disease on study up to starting a new anti-tumor therapy.
6. Duration of Response [ Time Frame: From randomization up to 65 months. ]
   Duration of response is defined as time from first confirmed objective response to disease progression per modified RECIST version 1.0 (by central assessment).

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria

• Diagnosis of metastatic adenocarcinoma of the colon or rectum that cannot, in the opinion of the investigator, be cured by surgical resection at the time of randomization
• Wild-type KRAS expressing mCRC from the primary tumor or metastasis.
• Failure of prior first-line oxaliplatin-based chemotherapy with bevacizumab (at least four therapeutic doses of oxaliplatin-based chemotherapy and bevacizumab) for mCRC.
• At least one uni-dimensionally measurable lesion per modified RECIST criteria.
• Cooperative Oncology Group (ECOG) performance status of 0 or 1
• Man or woman 18 years of age or older
• Hematology, chemistry, coagution, metabolic functions within normal or protocol-defined limits

Exclusion Criteria

• Previous irinotecan, anti-EGFr therapy (eg, cetuximab, panitumumab, erlotinib, gefitinib, lapatinib) or vaccine for the treatment of mCRC
• Radiotherapy ≤ 14 days before randomization
• Evidence of central nervous system (CNS) metastases
• Unresolved toxicities from prior anti-cancer therapy that, in the opinion of the investigator, precludes subject from participation
• History of other invasive primary cancer, except:
• Curatively resected or treated non-melanomatous skin cancer
• Curatively treated cervical carcinoma in situ
• Other primary solid tumor treated curatively and no treatment administered ≤ 2 years before randomization and, in the investigator's opinion, it is unlikely that there will be a recurrence ≤ 2 years post randomization

Medications

• C hronic daily treatment (as determined by the investigator) with aspirin (> 325 mg/day) or non steroidal anti inflammatory agents known to inhibit platelet function
• Infection requiring a course of systemic anti-infectives that was completed ≤ 14 days before randomization (exception can be made at the judgment of the investigator for oral treatment of an uncomplicated urinary tract infection [UTI])
• Subjects concurrently receiving any investigational agent or therapy ≤ 30 days before randomization

General:

• Significant cardiovascular risk as defined by the protocol
• History of peripheral arterial ischemia ≤ 24 weeks before randomization (subjects with brief, reversible, exercise-induced claudication are eligible)
• History of visceral arterial ischemia ≤ 24 weeks before randomization
• Significant bleeding risk:
• Major surgical procedure, open biopsy, or significant traumatic injury ≤ 28 days before randomization
• Anticipation of need for major surgical procedures during the course of the study
• C ore biopsy or other minor procedure, excluding placement of a vascular access device ≤ 7 days before randomization
• A ny significant bleeding that is not related to the primary colon tumor ≤ 24 weeks before randomization
• P re-existing bleeding diathesis or coagulopathy with the exception of well-controlled chronic anticoagulation therapy
• Serious or non-healing wounds, skin ulcers, or unhealed bone fractures
• Gastroduodenal ulcer(s) determined by endoscopy to be active or uncontrolled gastrointestinal ulcer ≤ 28 days before randomization
• History of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest x-ray (CXR) or computed tomography (CT) scan
• Clinically significant ascites
• Subjects known to be human immunodeficiency virus (HIV) positive or known to have chronic or active hepatitis B or C infection
• Men and women of childbearing potential (women who are post-menopausal < 52 weeks, not surgically sterilized, or not abstinent) who do not consent to use adequate contraception (according to institutional standard of care) during the course of the study and after the last date of receiving second-line treatment (24 weeks for women, 4 weeks for men)
• Women who test positive for serum or urine pregnancy test ≤ 72 hours before randomization or are breast-feeding
• Subjects allergic to any component that is part of the treatment regimen

Contacts and Locations

Sponsors and Collaborators

Amgen

Investigators

• Study Director: MD; Amgen

More Information

Additional Information:

AmgenTrials clinical trials website 

Publications:

Hecht JR, Cohn A, Dakhil S, Saleh M, Piperdi B, Cline-Burkhardt M, Tian Y, Go WY. SPIRITT: A Randomized, Multicenter, Phase II Study of Panitumumab with FOLFIRI and Bevacizumab with FOLFIRI as Second-Line Treatment in Patients with Unresectable Wild Type KRAS Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2015 Jun;14(2):72-80. doi: 10.1016/j.clcc.2014.12.009. Epub 2015 Jan 8.

• Responsible Party: Amgen
• ClinicalTrials.gov Identifier: NCT00418938
• Other Study ID Numbers: 20060141
• First Posted: January 5, 2007
• Results First Posted: March 28, 2014
• Last Update Posted: October 17, 2018
• Last Verified: September 2018

Keywords provided by Amgen:

EGFR; FOLFIRI; 2nd Line Therapy; 2nd Line mCRC Therapy; mCRC; Irinotecan; panitumumab; bevacizumab

Additional relevant MeSH terms:

Colorectal Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases; Leucovorin; Bevacizumab; Panitumumab; Fluorouracil; Irinotecan; Antineoplastic Agents, Immunological; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Physiological Effects of Drugs; Growth Inhibitors; Antimetabolites; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Immunosuppressive Agents; Immunologic Factors; Topoisomerase I Inhibitors; Topoisomerase Inhibitors